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Abstract
Background: Ozanimod, an oral immunomodulator, selectively targets sphingosine 1-phosphate receptors 1 and 5.
Objective: Evaluate efficacy, safety, and tolerability of ozanimod in relapsing multiple sclerosis.
Methods: In the RADIANCE Part A phase II study (NCT01628393), participants with relapsing multiple
sclerosis were randomized (1:1:1) to once-daily ozanimod hydrochloride (0.5 or 1 mg) or placebo. After
24 weeks, participants could enter a 2-year, dose-blinded extension. Ozanimod-treated participants continued their assigned dose; placebo participants were re-randomized (1:1) to ozanimod hydrochloride 0.5
or 1 mg (equivalent to ozanimod 0.46 and 0.92 mg).
Results: A total of 223 (89.6%) of the 249 participants completed the blinded extension. At 2 years of the
extension, the percentage of participants who were gadolinium-enhancing lesion-free ranged from 86.5%
to 94.6%. Unadjusted annualized relapse rate during the blinded extension (week 24—end of treatment)
was 0.32 for ozanimod hydrochloride 0.5 mg → ozanimod hydrochloride 0.5 mg, 0.18 for ozanimod
hydrochloride 1 mg → ozanimod hydrochloride 1 mg, 0.30 for placebo → ozanimod hydrochloride 0.5
mg, and 0.18 for placebo → ozanimod hydrochloride 1 mg. No second-degree or higher atrioventricular
block or serious opportunistic infection was reported.
Conclusion: Ozanimod demonstrated sustained efficacy in participants continuing treatment up to 2 years
and reached similar efficacy in participants who switched from placebo; no unexpected safety signals
emerged.
Keywords: Clinical trial, disease-modifying therapies, MRI, relapsing/remitting, T2 lesions, multiple
sclerosis
Date received: 23 January 2018; revised: 27 June 2018; accepted: 27 June 2018
Introduction
Multiple sclerosis (MS) is a complex inflammatory
disease in which autoreactive lymphocytes infiltrate
the central nervous system (CNS). Sphingosine
1-phosphate (S1P) is a phospholipid involved in lymphocyte migration and other physiological processes.
The initial S1P receptor modulator approved for treating relapsing multiple sclerosis (RMS), fingolimod
targets four of the five S1P receptors: S1P1, S1P3,
S1P4, and S1P5.1,2 Functional antagonism of S1P1 prevents the release of immune cells from lymph nodes,
while S1P5 modulation may be neuroprotective.3–5
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Ozanimod is a once-daily, oral immunomodulator
that selectively targets S1P1 and S1P5. In the placebocontrolled, phase II portion (Part A) of RADIANCE
(NCT01628393), ozanimod hydrochloride (HCl) 0.5
and 1 mg were associated with significant reductions
in mean cumulative number of gadolinium-enhancing
lesions and new/enlarging T2-hyperintense lesions
over weeks 12–24 relative to placebo, as well as
numerical, dose-dependent decreases in annualized
relapse rate (ARR) in participants with RMS.6 No
serious cardiac events, serious infections, or macular
edema were reported. We report results for an
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Figure 1. RADIANCE Part A design.

additional 2 years of participation in the blinded
extension of RADIANCE Part A.
Methods
Study design and participants
The design of RADIANCE Part A was previously
described.6 Briefly, RADIANCE Part A was a multicenter, randomized, double-blind, placebo-controlled,
phase II study of participants with RMS diagnosed
per the 2010 McDonald criteria.7 Study participants
were aged 18–55 years, with an Expanded Disability
Status Scale (EDSS) score 0–5.0 and ⩾1 relapse in
the 12 months prior to enrollment or ⩾1 relapse in the
prior 24 months plus ⩾1 gadolinium-enhancing magnetic resonance imaging (MRI) lesion in the previous
12 months. Those with progressive MS or disease
duration >15 years and EDSS score ⩽2.0 were
excluded.
Eligible participants were randomized (1:1:1) to oncedaily ozanimod HCl 0.5 mg (equivalent to ozanimod
0.46 mg), ozanimod HCl 1 mg (equivalent to ozanimod
0.92 mg), or placebo for 24 weeks. At week 24, study
participants could enter a 2-year, dose-blinded extension in which participants originally randomized to ozanimod HCl continued their assigned dose (ozanimod
HCl 0.5 mg → ozanimod HCl 0.5 mg and ozanimod
HCl 1 mg → ozanimod HCl 1 mg groups), and those
originally administered placebo were re-randomized
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(1:1) to ozanimod HCl 0.5 mg (placebo → ozanimod
HCl 0.5 mg group) or 1 mg (placebo → ozanimod HCl
1 mg group), as shown in Figure 1. Randomization was
stratified by country and performed centrally through
an interactive voice response system using a computergenerated sequence programmed by an independent,
unmasked, statistical team at the contract research
organization (Pharmaceutical Product Development).
During the extension, the sponsor and contract research
organization were unblinded to treatment assignment,
while investigators and participants remained blinded.
A dual assessor approach, with separate treating and
EDSS-examining investigators, was used to reduce
potential unblinding. A core-imaging facility (NeuroRx
Research, Montreal, Canada), blinded to treatment and
other outcomes, performed MRI measurements.
All participants, including those originally randomized
to ozanimod HCl during the placebo-controlled period,
underwent dose escalation with ozanimod HCl at
week 24 (baseline for the blinded extension) over
7 days (0.25 mg on days 1–4, 0.5 mg on days 5–7, and
then assigned dose starting on day 8) at the beginning
of the blinded extension to maintain blinding.

Standard protocol approvals, registrations, and
participant consents
The RADIANCE Part A extension was approved by
the institutional review board/ethics committee at each
participating site. The study protocol conformed to
journals.sagepub.com/home/msj
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Good Clinical Practice guidelines and the principles
outlined in the Declaration of Helsinki. All participants
provided written informed consent. The study is registered at ClinicalTrials.gov (NCT01628393).
Assessments
During the blinded extension, participants were
examined every 12 weeks. MRI was performed at
entry to and at 6 months, 1 year, and 2 years of the
blinded extension. A blinded treating physician supervised clinical management of the participant, including treatment-emergent adverse events (TEAEs). An
independent, blinded EDSS evaluator performed the
neurological examinations and completed the EDSS
assessment. Efficacy endpoints included mean number of gadolinium-enhancing lesions, proportions of
participants free of gadolinium-enhancing lesions,
mean number of new or enlarging T2-hyperintense
lesions on brain MRI, and unadjusted ARR.
Safety evaluations included the incidence and type of
TEAEs, serious TEAEs, TEAEs leading to treatment
discontinuation, pulmonary function tests, optical
coherence tomography, and laboratory testing. TEAEs
of special interest included infections, bradycardia,
heart conduction abnormalities, abnormal pulmonary
function tests, macular edema, hepatic effects, and
malignancies.
At week 24 (baseline of the blinded extension), all
participants were monitored for 6 hours after treatment (hourly vital signs and electrocardiograms
before and 6 hours after treatment initiation in the
blinded extension). Dermatologic exams were performed by the investigator at screening and every
6 months thereafter; any participant with suspicious
findings was referred to a dermatologist.
Statistical analysis
Descriptive statistics were used to describe outcomes
in the intent-to-treat population during the blinded
extension. Demographic characteristics and safety
data were pooled by ozanimod HCl-dose group (0.5
or 1 mg). Efficacy was examined in the dose subgroups as described above.
Results
Participant disposition
In total, 97.7% (252/258) of the participants completed the 24-week placebo-controlled period (ozanimod HCl 0.5 mg, n = 85; ozanimod HCl 1 mg, n = 82;
journals.sagepub.com/home/msj

placebo, n = 85). Three participants declined to enter
the blinded extension. A total of 126 participants
received ozanimod HCl 0.5 mg, and 123 received
ozanimod HCl 1 mg during the blinded extension
(Figure 2) between 1 May 2013 and 2 May 2016.
Demographics and disease characteristics of participants in the blinded extension were similar to the
baseline of the core period6 and across treatment
groups (Table 1). Overall, 89.6% (223/249) of participants in RADIANCE Part A who continued to the
blinded extension completed an additional 2 years,
with 11.1% (14/126) and 9.8% (12/123) of those randomized to ozanimod HCl 0.5 and 1 mg, respectively,
discontinuing study treatment prior to year 2. The
reasons for treatment discontinuation are summarized in Figure 2.
Efficacy
The mean number of gadolinium-enhancing lesions
remained low in participants who continued ozanimod HCl throughout the placebo-controlled6 and
blinded extension periods (Figure 3(a)). Among participants initially assigned to placebo who were rerandomized to ozanimod HCl, the mean number of
gadolinium-enhancing lesions decreased between
entry into the blinded extension at year 1 and remained
low at year 2. At entry into the blinded extension, the
proportion of participants free of gadolinium-enhancing lesions was 84.7% for ozanimod HCl 0.5 mg →
ozanimod HCl 0.5 mg, 87.7% for ozanimod HCl 1 mg
→ ozanimod HCl 1 mg, 58.5% for placebo → ozanimod HCl 0.5 mg, and 69.0% for placebo → ozanimod
HCl 1 mg; the proportions of participants free of gadolinium-enhancing lesions ranged from 91.1% to
92.9% at year 1 and from 86.5% to 94.6% at year 2
(Figure 3(b)). Ozanimod HCl showed a dosedependent trend in reducing the mean number of new
or enlarging T2 lesions (Figure 3(c)) from entry into
the blinded extension to year 1 and from year 1 to year
2. The effects of ozanimod HCl on the unadjusted
ARR seen during the placebo-controlled period were
maintained during the blinded extension (Figure 3(d))
for participants continuing ozanimod HCl and
decreased over the study period for those participants
initially randomized to placebo (Figure 3(d)).
Unadjusted ARR during the blinded extension was
0.32 for ozanimod HCl 0.5 mg → ozanimod HCl
0.5 mg, 0.18 for ozanimod HCl 1 mg → ozanimod
HCl 1 mg, 0.30 for placebo → ozanimod HCl 0.5 mg,
and 0.18 for placebo → ozanimod HCl 1 mg. Mean
EDSS remained stable during the blinded extension
period. Mean (standard deviation) change from baseline of the blinded extension at year 2 was 0.2 (0.85)
for the ozanimod HCl 0.5 mg → ozanimod HCl
1257
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Figure 2. Disposition.

0.5 mg group, 0.1 (0.64) for the ozanimod HCl 1 mg
→ ozanimod HCl 1 mg group, 0.3 (0.76) for the placebo → ozanimod HCl 0.5 mg group, and 0.2 (0.67)
for the placebo → ozanimod HCl 1 mg group.

Safety
Safety data are summarized in Table 2 and
Supplementary Table 1. The most common TEAEs
associated with ozanimod HCl were nasopharyngitis, upper respiratory tract infection, and increased
alanine aminotransferase (ALT). A total of 4.9%
(12/247) of participants had increases in ALT ⩾3times the upper limit of normal (ULN; ozanimod
HCl 0.5 mg, n = 4; ozanimod HCl 1 mg, n = 8). Of
these participants, two (ozanimod HCl 0.5 mg, n = 1;
1258

ozanimod HCl 1 mg, n = 1) had concurrent aspartate
aminotransferase (AST) elevations, while one participant, treated with ozanimod HCl 1 mg, had an
isolated AST elevation. There were no reports of
serious opportunistic infections during the blinded
extension. No clinically significant abnormalities in
pulmonary function tests and no cases of macular
edema or malignancy were reported during the
blinded extension. Four participants discontinued
treatment due to a TEAE during the 2-year blinded
extension (Table 2). These discontinuations were all
attributable to increased transaminases and were
protocol-specified (participants with confirmed
ALT or AST levels >5-times the ULN were required
to permanently discontinue study treatment). All
four participants recovered after discontinuation of
ozanimod HCl.
journals.sagepub.com/home/msj
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Table 1. Demographics and disease characteristics of the blinded extension population at study entry.

Mean age (SD), years
Female, n (%)
White, n (%)
Eastern Europe, n (%)
Mean time since MS symptom onset (SD),
years
Mean time since MS diagnosis (SD), years
Mean EDSS score (SD)
Mean relapses in the previous 12 months, n
(SD)
Mean relapses in the previous 24 months, n
(SD)
Mean gadolinium-enhancing lesions, n (SD)
Participants free of gadolinium-enhancing
lesions, n (%)
Participants who received prior MS
medication, n (%)

Placebo →
ozanimod HCl
0.5 mg, (n = 41)

Ozanimod HCl
0.5 mg → ozanimod
HCl 0.5 mg, (n = 85)

Placebo →
ozanimod HCl 1 mg,
(n = 42)

Ozanimod HCl 1 mg
→ ozanimod HCl
1 mg, (n = 81)

41 (8.01)
30 (73.2)
41 (100)
38 (92.7)
9.0 (7.05)

38.1 (9.26)
58 (68.2)
83 (97.6)
78 (91.8)
6.0 (6.49)

36.9 (8.69)
30 (71.4)
42 (100)
36 (85.7)
7.0 (7.05)

38.5 (9.90)
57 (70.4)
81 (100)
74 (91.4)
6.2 (5.81)

5.3 (5.19)
2.7 (1.19)
1.3 (0.68)

2.8 (5.02)
2.9 (1.29)
1.4 (0.95)

3.7 (5.11)
2.9 (1.38)
1.4 (0.62)

3.6 (4.46)
2.8 (1.18)
1.3 (0.71)

2.0 (1.22)

2.0 (1.69)

1.7 (0.75)

1.8 (1.05)

1.8 (3.73)
28 (68.3)

0.9 (1.43)
51 (60.0)

0.6 (1.38)
30 (71.4)

1.4 (2.78)
51 (63.0)

18 (43.9)

19 (22.4)

12 (28.6)

18 (22.2)

EDSS: Expanded Disability Status Scale; MS: multiple sclerosis; SD: standard deviation.
Demographic and baseline characteristics at entry into the double-blind, placebo-controlled phase of RADIANCE Part A.

A total of 12 participants receiving ozanimod HCl
0.5 mg experienced ⩾1 serious TEAE, including
acute myocardial infarction, (n = 1; 18 months after
first dose in a participant who was 43 years old at randomization and had a medical history of lupus and
hypertension) and hepatitis (n = 1; in a participant
with a recent history of multiple bee stings and who
was negative for viral hepatitis etiologies and antinuclear antibodies; Table 2; Supplementary Table 2).
Nine participants receiving ozanimod HCl 1 mg
reported a serious TEAE, including a case of moderate pancytopenia that resolved without interruption of
treatment. No serious TEAE occurred in more than
one participant, and none was considered related to
ozanimod HCl.
The maximum mean decrease in heart rate from predose baseline of the extension was 0.6 bpm, which
was observed at 4 hours post-treatment on the first
day of dose escalation at entry into the blinded extension in the placebo → ozanimod HCl 0.5 mg group; in
participants continuing ozanimod HCl, mean heart
rate did not decrease relative to baseline. One participant, randomized to placebo → ozanimod HCl 1 mg,
experienced a decline in heart rate per vital sign measurement to below 45 bpm (specifically, 44 bpm),
which was asymptomatic; this participant had a baseline pre-dose heart rate of 55 bpm. No participant who
switched from placebo to ozanimod HCl had a

journals.sagepub.com/home/msj

decrease in heart rate of >20 bpm from pre-dose baseline during hours 1‒6 on the first day of the blinded
extension. There were no reports of second-degree or
higher atrioventricular block.
Hypertension was reported in 7.9% (10/126) of participants in the ozanimod HCl 0.5 mg group and 3.3%
(5/123) of participants in the 1 mg group, with one
case in the 0.5 mg group considered to be possibly
related to study drug. There was one case of hypertension that was considered serious but unrelated to
study drug in a participant (ozanimod HCl 0.5 mg
group) with pre-existing hypertension who was hospitalized for further cardiac evaluation and medication
adjustment. Herpes zoster was reported in five participants (ozanimod HCl 0.5 mg, n = 3; ozanimod HCl
1 mg, n = 2), although immunity was a requirement for
enrollment. No case was serious and none led to permanent discontinuation of study drug. No seizures
were reported during the study. No dermatologic cancers were observed.
During ozanimod exposure, four participants (all
treated with ozanimod HCl 1 mg) had absolute lymphocyte counts <200 cells/µL, which were observed
at weeks 12 and 48 (n = 1), 24 (n = 1), and 72 (n = 2) of
the blinded extension (no participant had absolute
lymphocyte counts <200 cells/µL during the core
period of the study8). The absolute lymphocyte count
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Figure 3. Efficacy outcomes: (a) mean number of gadolinium-enhancing lesions at year 1 and year 2 of the blinded
extension, (b) proportions of participants free of gadolinium-enhancing lesions during the blinded extension, (c) mean
number of new or enlarging T2 lesions over the entire study, and (d) unadjusted ARR over the entire study.
ARR: annualized relapse rate; GdE: gadolinium-enhancing; SEM: standard error of the mean.

Table 2. Safety summary.
Core period and blinded extension

Participants with ⩾1 TEAE, n (%)
Participants with ⩾1 treatment-related TEAE, n (%)
Participants with ⩾1 serious TEAE, n (%)
Participants with ⩾1 TEAE leading to treatment
discontinuation, n (%)
Treatment-related deaths, n (%)

Ozanimod HCl
0.5 mg, (n = 126)

Ozanimod HCl
1 mg, (n = 123)

99 (78.6)
5 (4.0)
12 (9.5)
3 (2.4)

93 (75.6)
4 (3.3)
9 (7.3)
1 (0.8)

0 (0)

0 (0)

TEAE: treatment-emergent adverse event.

reductions below 200 cells/µL were transient, with
none associated with infection or leading to study discontinuation. Three participants, all treated with ozanimod HCl 0.5 mg, had absolute neutrophil counts
<1000 cells/µL, one at baseline, one at week 48, and
one at week 96 of the blinded extension.
1260

Discussion
In the blinded extension of the phase II portion of
RADIANCE, both doses of ozanimod HCl (0.5 and
1 mg) demonstrated continued efficacy over 2 years,
as shown by low levels of MRI lesion activity and low
unadjusted ARR, with apparent greater efficacy on
journals.sagepub.com/home/msj
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both MRI and clinical disease measures for ozanimod
HCl 1 mg versus ozanimod HCl 0.5 mg. In addition,
the efficacy observed in participants who initially
received placebo approximated that observed in participants who received ozanimod HCl continuously
throughout the placebo-controlled portion of the
study and the blinded extension. Consistent with the
24-week placebo-controlled treatment period,6 gadolinium-enhancing and new or enlarging T2 lesion
numbers remained low in all four treatment groups
during the 2-year blinded extension.
Safety plays a major role in treatment preference
among individuals with MS,9 and adverse events (e.g.
injection reactions and flu-like symptoms with injectable therapies and gastrointestinal side effects, headache, heart rate effects, and macular edema with oral
therapies) are among the most common reasons for
the discontinuation of MS treatments.10 The use of
ozanimod HCl for over 2 years was well tolerated,
with few participants discontinuing for side effects or
safety reasons. TEAEs during the 2-year blinded
extension were consistent with those seen during the
placebo-controlled period, with no apparent increase
over time or differences between ozanimod HCl 0.5
and 1 mg. In the blinded extension period, 4.9% of
participants receiving ozanimod HCl experienced
increases in ALT ⩾3-times the ULN, with the majority of ALT elevations occurring in participants who
switched from placebo. Most cases of elevated liver
enzymes were transient and did not require discontinuation of ozanimod HCl. Based on protocol
requirements, four participants discontinued from the
study with an ALT ⩾5-times ULN; all recovered after
drug discontinuation.
Ozanimod was administered in a dose escalation regimen. In the RADIANCE Part A blinded extension,
there were no reports of clinically significant cardiac
conduction abnormalities associated with ozanimod
HCl, including no second-degree or higher atrioventricular block, and no clinically meaningful bradycardia was observed, consistent with the results of the
placebo-controlled period.6 It should be noted that
individuals with certain clinically relevant cardiovascular conditions were excluded from the study,6 and
<20% of participants had a history of cardiovascular
disorders. Additional studies will help to further
define the safety profile of ozanimod.
Results of extension studies are sometimes biased by
participant attrition. However, this analysis benefited
from high retention, with 88.9% of participants randomized to ozanimod HCl 0.5 mg and 90.2% of participants administered ozanimod HCl 1 mg completing
journals.sagepub.com/home/msj

2 years of treatment. The participant population in
this study was similar to that of other phase II trials
of participants with MS administered other selective
S1P receptor modulators.11 Limitations of these data
include lack of a control arm during the blinded
extension, relatively small sample size, and a predominantly white, Eastern European population.
The phase III portion of RADIANCE (Part B,
NCT02047734) is larger, comprising 1313 participants with RMS randomized (1:1:1) to ozanimod
HCl 0.5 mg, ozanimod HCl 1 mg, or intramuscular
interferon beta-1a for 24 months. In addition,
SUNBEAM (NCT02294058), a similarly designed
phase III study, enrolled 1346 participants with
RMS. Those participating in SUNBEAM received
ozanimod HCl 0.5 mg, ozanimod HCl 1 mg, or intramuscular interferon beta-1a for at least 12 months.
Together, these two phase III studies will provide
comprehensive data on the benefits and risks of this
potential new treatment for RMS.
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